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Abstract—Alzheimer’s disease (AD) is a chronic neurodegen-
erative disease, serving as the most common form of dementia
among the elderly population. AD targets various neurological
processes in humans such as the visual pathway and hence
resulting in various forms of visual abnormalities. Several studies
have reported the loss of retinal ganglion cells, reduced thickness
of nerve fibre layers (NFL) and damage of the optic nerve head
and fiber layers. These findings suggest a putative link between
AD and visual function deficits.
As genetic defects have been found to be associated with AD,
it is possible to experimentally mimic this condition in animal
models. AD gene mutations discovered in human amyloid pre-
cursor protein (APP), presenilin 1/2 (PS1/PS2) and microtubule-
associated tau protein have been used to engineer AD animal
models.
In this review, we discuss the underlying molecular mecha-
nisms of AD in terms of amyloidogenesis and tauopathies, as well
as explain the pathological changes leading to vision loss in AD
patients. Subsequently, the biology of the genes/proteins which
have a causative link to AD, including APP, PS1 and PS2 will be
discussed. Several recent reports of retinal degeneration in AD
transgenic mouse models are selected to examine the relationship
between AD and visual disturbance. We believe that a well-
established method to generate transgenic mice will enhance
our understanding of AD pathology and its correlation with
retinal degeneration, leading to possible detection and treatment
methods for AD.
I. INTRODUCTION
ALZHEIMER’S disease (AD) is a chronic neurodegen-erative disease, serving as the most common form of
dementia among the elderly population. Recently, findings of
people carrying the AD mutated gene, such as those afflicted
with Familial Alzheimers Disease (FAD), have an early onset
of AD at around 40 years of age [1], [2]. AD is characterized
by insidious onset of progressive decline in cognitive function
[3], [4]. Patients diagnosed with AD tend to have pathological
features of neuronal loss, neurofibrillary tangles (NFT) and
neuritic plaques [5], [6]. Characteristic lesions in AD are senile
or neuritic plaques, consisting of amyloid-β (Aβ) deposition,
NFT, that associate with tau protein pathology, which all lead
to the degeneration of neurons and synapses in the brain [2],
[4], [7].
One of the first symptoms AD patients tend to report is
visual abnormalities. Indeed, it is common for AD patients
or people who suffer from other neurodegenerative diseases
to have deficits in visual functions [1], [8]. A possible cause
could be the accumulation of Aβ peptide that has been
observed in the lens fibre cells of AD patients. Tauopathy
in retinal degeneration is also suspected as a contributor.
Clinical data has indicated that glaucoma patients who have
a decrease of overall tau protein level in the retina still have
increased amounts of abnormal hyperphosphorylated tau [9]–
[11]. Patients with elevated amounts of both Aβ42 and tau
due to glaucoma and diabetic retinopathy also have elevated
levels of tau in the vitreous body [12]. Studies have indicated
links between ocular diseases, such as glaucoma and AD [8],
[13], [14]. Studying these ocular diseases may provide more
information on the vision deficits in AD patients. Furthermore,
the characteristics and relationship of AD in neural pathology
of the brain and retinal pathology of the eye may be uncovered.
II. PATHOLOGY OF AD AND BIOLOGICAL MECHANISMS OF
NEURODEGENERATION IN AD
A. Aβ and its precursor form
Aβ peptides and amyloid plaques are pathological signa-
tures of AD and have been studied in-depth for decades. Amy-
loid plaques are composed of Aβ and non-Aβ components
such as ubiquitin and alpha-synuclein [14]. These elements are
found to accumulate around meningeal and cerebral vessels
and in the gray matter [15]. Since Aβ is produced by the
cleavage of amyloid precursor protein (APP), different groups
of enzymes responsible for this cleavage are key factors to
the expression of Aβ in the cell tissues. The cleavage of APP
can undergo two different pathways - a non-amyloidogenic
pathway and an amyloidogenic pathway.
The non-amyloidogenic pathway cleavage is completed by
α-secretase followed by γ-secretase, cleaving APP into sAPP
α amino (N) terminal extodomain and the non-pathogenic
P3 fragment. The cleavage of APP by α-secretase prevents
the formation of Aβ [15]. On the other hand, the cleavage of
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APP by β- and then γ -secretases through the amyloidogenic
pathway contributes to the formation of Aβ. The first cleavage
conducted by β-secretase releases sAPP β, which undergoes
further deletion by the γ-secretase enzyme complexes to
produce Aβ [15].
In amyloidogenic pathway, two types of Aβ, Aβ40 and
Aβ42, can be generated by the cleavage of γ-secretase.
Different forms of Aβ have different effects. Aβ40 isoform
prevents the formation of deposits, whereas Aβ42 has the
opposite effect [16]. Recent research has indicated that the
hydrophobic nature of Aβ42 may be prone to aggregation
which leads to the formation of Aβ deposits and plaques
in brain tissues [15]. According to the review of Morrissette
et al, 2008, the transgenic AD animal models demonstrated
similar plaque formation with Aβ42 accumulation supporting
the neurotoxic function of Aβ42. Interestingly, it is thought
that the amount of oligomeric Aβ formation is not proportional
to the degree of cognitive dysfunction, but rather the onset of
the cognitive decline precedes the formation of plaques [16].
1) APP mutant genes: Genes implicated in AD include
APP and presenilin 1/2 (PS1/PS2), among others. Carriers
of genetic defects often develop AD at an earlier stage of
life than those AD patients who do not have genetic defects,
although the familial forms of AD are uncommon; two known
forms of APP mutation are the London and Swedish mutations
[15], [17]. The London mutation is a missense mutation of
codon 717 with valine replaced by isoleucine, which enhances
fibrillogenic Aβ42 production. The Swedish double mutations
at codons 670 and 671 increase Aβ40 and 42 formation. Other
missense mutations targeting the pathway of Aβ production
often result in more Aβ42 than Aβ40 [17]. The discovery of
mutations that appear causal to AD has enabled the engineer-
ing of transgenic animal models to study the pathogenesis of
AD in a more effective way (see below).
2) Presenilins PS1 & PS2 mutations: The hydrophobic
nature of Aβ42 may be prone to aggregation which leads to the
formation of Aβ deposits and plaques in brain tissues [15]. In
this sense, the mutation of γ-secretase enzyme complexes can
trigger the mass deposition of Aβ plaques. The components
of γ-secretase complex include PS1, PS2, nicastrin, anterior
pharynx defective and presenillin enhancer 2 [15]. Mutations
of PS1 and PS2 are found on chromosomes 14 and 1, respec-
tively. The presenilin gene mutations are autosomal dominant.
PS1 mutations are associated with early onset of familial
Alzheimers disease (FAD) whereas PS2 mutations are involved
in the late onset of sporadic AD. Although the mutations differ
on AD onset, they both increase the production of Aβ42 [18].
PS1 and PS2 mutations in transgenic mice are believed to
interfere with the homeostasis of calcium [17]. Calcium re-
lease is up-regulated by elevating Inositol trisphosphate (IP3),
leading to an increase in neuronal calcium. IP3 is a secondary
messenger molecule used in signal transduction and lipid
signalling. This directly affects the synaptic plasticity, which
may trigger AD and memory deficit [18]. In addition, mutated
human PS1 transgene appears to alter fast axonal transport
and induce tau hyperphosphorylation [18]. Intracellular Aβ
in the soluble form rather than the insoluble was found to
be responsible for synaptic dysfunction by interfering with
the intracellular calcium homeostasis and by interacting with
abnormal tau [18]. By looking into presenilin mutant genes,
we can further investigate the responsibility of the intracellular
calcium in AD pathology.
B. Tau
1) Functions of Tau: Another hallmark of the AD is
neurofibrillary tangles (NFT), of which tau is a major com-
ponent. Tau is one of the families of microtubule-associated
proteins (MAP), important in axonal transport. Disregulation
of tau leads to neurodegenerative disorders caused by the
disruption of the communication paths between neuronal cells.
Thus, understanding the mechanisms and the factors inducing
tauopathy is essential for the development of treatments for
neurodegenerative disorders.
A variety of tau isoforms can be found in the human brain.
Different types of tau are produced by alternative splicing,
in which select exons of genes are expressed or skipped,
translating into different isoforms of the protein product. Six
different forms (ranging from 45 to 65 kDa) can be found in
human tau [19]. Owing to different conformations, such as the
alternative splicing of exon 10, tau isoforms are expressed with
specific functions in different regions [19]. Tau proteins help
to maintain the integrity of microtubule network in neurons.
The N-terminal of tau projected from the microtubule surface
interacts with other cytoskeletal components [20] and the C-
terminal regulates the microtubule polymerization [21]–[24].
Therefore, the multi-binding sites of tau may be of great
importance in stabilization, organization, axonal transport and
the communication within the neuronal cells.
Apart from the brain tissues, depositions of NFT are also
found in other regions of the body such as the heart, skeletal
muscles, lungs and kidneys in rats as well as in human
fibroblasts [25] and pancreas [26]. Indications show that AD
can be triggered by inflammations and other risk factors not
localized in the CNS but in peripheral areas.
A variety of tau isoforms can be found in the human brain.
Different types of tau are produced by alternative splicing.
Six different forms (ranging from 45 to 65 kDa) can be
found in human tau [19]. Owing to different conformations,
especially the alternative splicing of exon 10 inducing different
combination of three or four binding repeats, tau isoforms
are expressed with specific functions at different regions [19].
Tau proteins help to maintain the integrity of microtubule
network in neurons. The N-terminal of tau projected from
the microtubule surface interacts with other cytoskeletal com-
ponents [20] and the C-terminal regulates the microtubule
polymerization [21]–[24]. Therefore, the multi-binding sites of
tau may be of great importance in stabilization, organization,
axonal transport and the communication within the neuronal
cells.
2) Hyperphosphorylated tau and tauopathies: In a neu-
rodegenerative condition like Alzheimers disease, the neuronal
cells undergo an irregular cellular cycle leading to neuronal
cell apoptosis and potentially neurodegeneration. The abnor-
mal cell cycle may result from extrinsic sources like mitogen
factors and oxidative stress, which affect phosphorylation
A REVIEW ON THE ALZHEIMER DISEASE ANIMAL MODELS AND RETINAL DEGENERATION 3
cascades [11], [27], [28]. The phosphorylation of tau is reg-
ulated by various cascade signalling pathways [27], with Tau
serving as a possible endpoint to these cascades. Abnormal
hyperphosphorylation of tau is crucial in the pathogenesis of
AD.
NFT deposition is first found in the hippocampus structures
before the cortex in AD patients [28]. However, it seems
that the development of the NFT has no correlation with the
memory dysfunction. The improvement of cognitive function
after the suppression of transgene irrespective of the NFT
involves neuronal remodelling like improved synaptic function
and decreased synaptic loss in Tauopathy [29]. As a conse-
quence, the role of hyperphosphorylated tau in neuropathy is
still unknown.
C. Correlation of Aβ with tau
Various hypotheses have been established regarding Aβ
and amyloid plaque in relation to hyperphosphorylated tau.
One popular hypothesis is the amyloid cascade. It has been
suggested that Aβ is the triggering point of inducing AD, with
the downstream regulation of tauopathy and cognitive deficit.
It is believed Aβ formation precedes other factors like
tauopathy. This is supported by results in transgenic mice that
over-expression of APP leads to the hyperphosphorylation of
tau [16]. The suppression of tau can improve the cognitive
functions even with APP overexpression [16]. This suggests
that both Aβ and tau contribute to cognitive impairment in
AD. It has been noted that the specific time and period to
suppress the mutated tau in Tg4510 strain mice may provide
clues regarding the onset of the cognitive dysfunction [30].
Aβ prohibiting the function of proteasome may affect the
clearance of the aggregated tau and NFT [16]. Moreover, the
phosphorylation of tau and its microtubule binding ability are
regulated by different signalling pathways and Aβ is found
exerting its effect on the glycogen synthase kinase 3β and the
cyclin-dependent kinase 5 [16]. All evidence points to the fact
that tau can be the mediator for the regulation of Aβ under a
feedback mechanism with Aβ.
III. VISION PROBLEM/LOSS FOR AD PATIENT
A. Aetiology of vision loss in AD patients
Neurodegenerative disease patients such as AD, often suffer
from some form of vision deficit due to pathological changes
in the retina. Currently, there are three potential mechanisms of
vision loss reported by AD patients. These three mechanisms
have been termed: 1) the broad-band pathway [31], 2) glau-
coma [32], [33]; and 3) the ventral and dorsal streams of vision
[13]. These mechanisms have been the focus of researches
attempting to link AD and the deficit in vision.
These three mechanisms can be understood by considering
the interplay between the eye and the brain. Like other regions
of the brain, the retina is derived from the neural tube. The
retina is an integral part of the central nervous system by
generating neural signals when light is detected. The signals
are passed into the optic nerve which is directly connected to
the visual cortex in the brain. The first two mechanisms are
linked to the initial reception of the light in the retina while
the third mechanism correlates directly to the visual cortex in
the brain.
The broad-band pathway and glaucoma mechanisms share
similar aetiologies. The broad-band pathway is one of the
two traditional pathways of the pre-cortical visual system
[34], [35]. This broad-band pathway is the magnocellular
pathway, which originates in the magnocellular retinal gan-
glion cells (M-cells) [34], [35]. The theory behind the broad-
band pathway suggests that the degeneration of the M-cells
is responsible for the visual impairment in AD. With new
technological techniques, studies have shown a decline in
retinal ganglion cells (RGC) in AD patients. There is evidence
suggesting that the reduction of RGCs is parallel with severity
of AD [5], [36], however, specific loss of M-cells in AD
appears to be weakly supported. To date, only one study by
Sadun et al [13] has shown support for the degeneration of
M-cells being linked with AD vision impairment.
Glaucoma, the second mechanism, is thought to be similarly
connected to AD as the broad-band pathway. Glaucoma is
one of the worlds leading causes of vision loss [9]. It is
characterized by the loss of RGC and cupping of the optic
nerve head caused by increased intraocular pressure due to the
buildup of aqueous humor leading to swelling and a reduced
total number of axons in the optic nerve. Studies noted that
AD patients have a 25% higher glaucoma rate compared to
6% in control group. Biological similarities have been noted
between glaucoma and AD, with many studies showing the
loss of RGCs in AD patients with some levels of M-cell loss
which are thought to be the first cells to die in glaucoma
[9], [10]. Other similarities exist but RGC loss is reported as
the primary similarity between these conditions [10] however
there is no definite study showing that the underlying causes
of the diseases are the same [10].
The third mechanism being suggested is the ventral and
dorsal pathways. The ventral and dorsal pathways are the what,
where and how of the visual cortex. The ventral pathway is
the what, responsible for object recognition and color stimuli.
The dorsal pathway is the where and how, responsible for
perception and motion [37]. Deficits in both ventral and
dorsal pathways have been observed in patients with AD,
with evidence that impairment of both pathways occurs in
AD patients. However, methodological issues may have been
biased in the findings of the impairment and hence no firm
conclusion can be drawn relating AD vision deficit with dorsal
and ventral pathways.
All three mechanisms have supporting experimental evi-
dence, however none are conclusive. As such, it is important
to study the pathological changes more precisely in order to
determine the correct mechanisms involved in the vision loss
of AD patients. More likely, the visual loss is a combination of
all three mechanisms, but this is only speculative, as all three
mechanisms contribute to the visual abnormalities reported by
AD patients.
1) Clinical findings of AD patients related to broad-band
pathway: Retinal abnormalities observed in AD patients were
first noted by Hinton et al. [38] and later confirmed by
Blanks et al. [5], [6], [36]. The abnormalities involve RGC
loss, reduction of nerve fibre layer (NFL) thickness and more
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recently, tau pathology. These changes could be related to the
characteristic lesions seen in the brains of AD patients, such
as Aβ plaques and NFT, however, little is known about the
proposed relation.
Sadun et al. [13] also found similar results where AD
patients had a reduced axonal density and RGC count than the
elderly controls. However, this was contradicted by Curcio et
al [39] and Davies et al [40] showing no evidence of significant
abnormalities between axonal density and RGCs between AD
and the elderly controls. A recent study by Bersha et al [26]
found that patients with AD showed a significant narrowing
of the venous blood column and a significantly reduced blood
flow to the retinal veins. Studies also showed differences in
the optic nerve fibre density. Some findings showed a reduced
density while others showed no difference [39].
2) Clinical findings of AD patients related to glaucoma:
As mentioned before, many studies have also shown a link
between glaucoma and AD. Chandra et al [15] found that
an increased risk of glaucoma existed in patients with AD
after studying the contributory causes of death in AD patients.
Bayer et al [33] supported this by reporting that AD patients
had a 25% rate of glaucoma as compared to a 6.5% in the
controls (n=186). Another study supported this finding which
found a 25% rate of glaucoma in AD patients as compared
to 5.2% in the control group (n=116). However, other studies
have shown no association between the two diseases. In a
large scale glaucoma study (n=15000+), there was no evident
increase in the rate of AD among the glaucoma patients
[41]. Another study found that only 1 out of 38 AD patients
had glaucoma, which contradicts the association between the
diseases [42].
3) Clinical findings of AD patients related to dorsal and
ventral pathways: Several studies have reported the impair-
ment of object and facial recognition and color and pattern
processing [13], [34], [41], [43]–[46] in AD patients. A few
studies have shown deficits with visio-spatial processing, mo-
tor coordination and motion perception [26], [34], [47]. Many
studies have placed a higher importance on the ventral pathway
rather than the dorsal pathway, as most studies showed a higher
impairment rate with skills related to the ventral pathway.
Bouras et al [48], Arnold et al [37] and Van et al [49] found
that NFT formed in higher density in the ventral stream as
compared to the dorsal stream, signifying a higher degree
of damage in the ventral pathway. However, Cronin-Golomb
et al [44] showed that while AD patients had difficulty with
visual tasks, the backward pattern masking performance could
explain 50% of the variance in the participants cognitive
performances.
The three possible mechanisms discussed above, show con-
tradictory results. This could be related to the inconsistency
between the methodologies and study groups. Many factors
also have an impact to the findings, such as the level of
education, age, gender and sample size. All these factors
contribute to the results reported by the separate investigative
studies. As it is nearly impossible to completely standardize
the factors and methodologies in a study like this, a more
effective and efficient technique to study this link should
be investigated. To do this, it is often advisable to utilize
appropriate animal models, in order to solve the questions of
what mechanism links the visual deficit to AD.
IV. AD ANIMAL MODELS (TRANSGENIC MICE) FOR
STUDYING VISION LOSS IN AD PATIENTS
Studying AD in human subjects has many severe restrictions
that hamper the study process. These restrictions range from
ethical approval to patient consent. They also include the
time frame of AD onset in humans, the sample sizes and
the unpredictability of human pathology. Even after ethical
approval and patient consent, studying AD in the brain and
retina currently requires post-mortem samples, which are
difficult to obtain. With these restrictions, researchers have
turned to alternative means to study AD. Mouse models are
widely used for their rapid onset of the disease process and are
relatively easy to engineer with current transgenic technology.
Researchers commonly use transgenic animal models to mimic
AD in humans. Several designs of AD animal models are used,
ranging from the single transgenic to triple transgenic (3xTg)
mouse models. Not only do these models offer clues about
the neurodegenerative diseases, but are also comparatively
more cost and time effective. These models have played an
important role in many advances in AD pathology.
A. Transgenic mice -APP mutant gene
One of the mouse models well-utilized for studying AD
was developed by Karen Hsiao Ashe [20]. The behaviours and
histopathology observed in Tg2576 mice have shown similari-
ties to those found in AD. Some studies have indicated that the
impairment in learning and memory in spatial reference and
alternation was in correlation with the amounts of Aβ and the
formation of amyloid plaques. The degree of impairment was
obvious in 9-month mice with robust increase of the amount
of Aβ and plaque. The more neurotoxic Aβ42 was found to
be substantially increased [16]. Other studies suggested that
the concentration of Aβ did not proportionally increase with
the APP expression with age [20].
The ages of AD onset were variable among studies in
Tg2576 mice, with the earliest onset being 3 months and the
latest at 15 months of age [40], [43], [44], [50], depending
on the targets focused and the protocols used. The soluble
oligomic Aβ has been found as early as 2 months of age
with synaptic dysfunction occurring before the concrete Aβ
deposition existed [17]. Therefore, transgenic APPswe mice
have the AD onset of about 6 to 10 months of age together
with a surge in the diffuse and oligomeric Aβ. They may be
essential tools for studying the onset of AD.
B. Double Transgenic mice - APP and PS1/2 mutant genes
Several types of transgenic mutant mice were manipulated
to carry a single mutated PS1 or PS2 gene. Though over-
production of Aβ42 occurred in this kind of single mutant
mice, no lesions were observed in brain tissues [17]. On the
contrary, the construct of human mutated PS1 or PS2 with
additional types of mutated genes seems to reinforce the patho-
genesis of AD by increasing opportunities of proteolysis of
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APP via the amyloidogenic pathway. Various transgenic mice
expressing different kinds of mutated PS1 and mutated APP
genes were engineered and different levels of Aβ expressions
were observed.
The APPswe mouse model Tg2576 crossed with human mu-
tation gene PS1M146V can produce Aβ deposits at the age of
6 months, which is around 3 months earlier than Tg2576 mice.
It appears that the more mutated genes inserted in the construct
of the transgenic animal models, the earlier the occurrence
of the Aβ peptide and Aβ plaque accumulation. Other Tg
mice with Swedish, Dutch and London mutations also have
elevated intraneuronal Aβ accumulation in the hippocampus
and cortical pyramidal neurons before the existence of the Aβ
plaques [32]. The PS1 knockin mice models also expressed
similar results. The aggregation of N-modified Aβ 42 in
neurons and the axonal degeneration at the age of 2 months
were observed in the APP/PS1KI mice models. The loss of
CA1 neurons with working memory deficits and reduction
of motor performance were found at the age of 6 months
[32]. As a consequence, presenilin mutation together with APP
mutation can increase the accumulation of Aβ peptide and
plaques.
C. Triple transgenic mice APP, PS1 and tau mutant genes
The transgenic mice with mutated APP gene expression
may be a more appropriate AD mouse model to mimic
the development of AD occurrence in humans. The triple
transgenic mice model expressing PS1M146V, APPswe, and
tauP301L transgenes was proven to be a promising mouse
model producing plaques and tangles in the brain tissues. The
PS1 knockin mouse originated from a hybrid 129/C57BL6, is
utilized for generation of the triple transgenic mice [51].
Specific regions of human APP and tau transgene expressed
in 3xTg mice were found to be the same as AD human
brain regions including hippocampus and cerebral cortex [52].
The distribution of intraneuronal Aβ in the 3xTg mices brain
tissues resembles AD brains found in human. Aβ is first
discovered in the neocortical regions and it later spreads to
CA1 pyramidal neurons of the hippocampus of 3xTg mice
at 6 months of age [52]. The aggregated tau was first found
within pyramidal neurons of CA1 subfield of hippocampus in
the 3xTg mice [53]. Therefore, 3xTg mouse model may be
a good model mimicking tau and later NFT formation and
the pathway of distribution among the human brain regions.
However, tau and hyperphosphorylated tau did not co-exist
with Aβ at the same age of mice. Tau formation was first
observed in the 6-month-old mice, but the abnormal human
hyperphosphorylated tau exists later in older mice. It can then
be found in both hippocampus and cortical regions by the age
of 15 months [52].
V. RETINAL DEGENERATION IN AD MOUSE MODELS
In this part, we will review and examine recent research
utilizing AD animal models to study AD and retinal de-
generation. Recent findings can be grouped into three main
categories -neuronal cell loss, neuronal signal interruption and
tau pathology. The four studies below are collectively used to
show the relationships between retinal degeneration and AD
in mouse models.
Recent studies on animal models have shown that retinal
abnormalities in AD are associated with amyloidosis. Aβ
accumulation in the retinal vasculature can lead to activation of
apoptosis in neurons, recruitment of MCP-1 and activation of
microglia cells. Tau filament formation has also been observed
in the retina, but it is independent of axonal degeneration.
Studies also show that Aβ and APP accumulation in the retina
is age dependent and the formation of Aβ plaques occurs
earlier in the brain than it does in the retina. This gives rise
to the idea that APP is processed differently in the brain than
in retina; APP appears approximately at the same time period
in these areas, but Aβ plaques occur at different times.
Ning et al., (2008) using two strains of double transgenic
mice (Table I) have produced results showing accumulation of
amyloid-β in the retina of the these transgenic mice. Aβ was
absent in young mice, indicating that Aβ deposits were formed
later than 7.8 months of age but before 27 months as the Aβ
was strongly reactive in the older mice. Presence of APP was
significantly stronger in aged mice compared to younger mice,
representing age dependent amyloidosis. The outer nuclear
layer (ONL) was negative for APP while the inner plexiform
layer (IPL) and inner nuclear layer (INL) were strongly
reactive to the presence of APP. Microglia was detected in
surrounding cells in ganglion cell layer (GCL), IPL and OPL
of the older mice. Microglias act as an immunodefense system
in the CNS to clean up possible harmful factors in the CNS.
MCP-1, which is responsible for the recruitment of T-cells,
monocytes and dendrite cells to sites of injury, was present
in the cytoplasmic compartment in the GCL, but not outside
GCL. Together with the presence of microglia and MCP-1 in
the GCL, a significant increase in Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) positive cells
were detected in the transgenic mice.
Perez et al., (2009) found that plaques were first formed
in the retina at approximately 12 months in Tg mice and
were observed to affect the retinal structure. The distribution
of important membrane associated SNAP receptor protein
syntaxin 1 was disrupted. The interference of syntaxin 1 could
be one of the causes leading to visual impairment in AD.
Microglia activity was detected with a significant increase in
the retina between the Tg and non-Tg mice in all ages. ERG
detected a significant decrease in alpha and beta waves of Tg
and non-Tg mice at low light intensities, representing retinal
degeneration of some forms. The difference of alpha and beta
waves may be correlated with the Aβ plaques and increased
microglia activities, interfering retinal neuronal transmission
and disrupting the normal physiology of the retina.
Dutescu et al., (2009) studied the differences and connec-
tions between the brain and retina of two AD double Tg
mice models (Tg2576 and APP/PS1 double transgenic mice
model). Expression of APP was detected at the age of 14
months in Tg2576. Along with APP; Aβ was also detected
in Tg2576 at the same age as non-Tg mice. Detection of
positive Aβ in peripheral retina of vacuolar structures of the
GCL indicted damages to capillaries in both mice models. The
double Tg mice model revealed Aβ labeling in the cytoplasmic
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Title Year &
Authors
AD
Animal
Model
Age Significance
β-Amyloid
Deposition
and Functional
Impairment
in Retinal of
APPswe/PS1E9
Tg model of AD
2008,
Ning et
al
APPswe/
PS1 E9
12-16
months
and
19-21
months
Aβ interferes
with neuronal
signal
transmission,
no direct
observation of
neuronal cell
loss
Amyloid-B
deposits lead
to retinal
degeneration in
a mouse model
of Alzheimer’s
Disease
2009,
Perez et
al
Strain 1:
APP/PS1,
Strain 2:
APPswe
/PS1
DeltaE9
Strain
1: 7.8
and 27
months
Strain
2: 10.5
months
A plaques
detected in
retina lead
to apoptosis
of neural
cells, causing
neuronal cell
loss
Amyloid Precur-
sor Protein Pro-
cessing and Reti-
nal Pathology in
Mouse models of
Alzheimer’s Dis-
ease
2009,
Dutescu
et al
Strain
1:Tg2576,
Strain
2: APP-
swe/
PS1-dE9
Strain
1: 6-12
months,
Strain
2: 2-18
months
APP processing
is different
between the
brain and retina
of different Tg
mice
Tau inclusions in
retinal ganglion
cells of human
P301S tau Tg
Mice, effects on
axonal viability
2009,
Gas-
parini et
al
P301S 1-6
months
Tau pathology
increases rate
of axonal
pathology
TABLE I
SUMMARY OF RETINA AND AD RESEARCH
compartment of RGC and INL cells similar to those labeled
in the single transgenic model - Tg2576. Analysis of Aβ40
and Aβ42 showed significantly higher concentrations in Tg
mice as compared to their non-Tg age group in the retina.
Furthermore, the onset of Aβ and APP was different between
the brain and retina of AD mice models, suggesting formation
of Aβ was earlier in the brain.
Gasparini et al., (2009) studied the tau pathology in the
retina of AD mouse models. Tau was hyperphosphorylated in
the Tg mice and the reactivity was consistent with tau pathol-
ogy in the brain. Hyperphosphorylated tau was positive in cell
bodies, axons and proximal dendrites in RGC of Tg mice,
but immunoreactivity studies were positive for filamentous tau
associated with degenerated axons and dendrites. Abnormal
axon swellings were observed in the RGC. These observations
revealed that axonal pathology occurs before tau accumula-
tion, meaning that axonal degeneration is independent of tau
filament formation in the retina.
A. Discussion
In summary, APP is the precursor of Aβ and its concentra-
tion is age dependent. Aβ is considered here as a possible
mechanism that stimulates the activation and presence of
microglia and MCP-1 in the retina. This is thought to cause
apoptosis as shown by the significant increase in TUNEL
positive cells of Tg mice.
APP processing is believed to be different between the brain
and retina due to discrete time periods of Aβ formation. Retina
of Tg2576 showed a significant difference between α- and β-
secretase in the retina while the brain had an equal amount.
Double transgenic strain APP/PS1, showed minimal of both
α- and β-secretase in the retina, suggesting the differences
lay in APP processing. Formation of tau filaments in the
retina is also believed to be one of the causes of the neuronal
loss or disruption in retinal degeneration. However, Gasparini
(2009) revealed that axonal degeneration was independent of
tau filament formation, suggesting that tau filament increased
the rate of axonal degeneration but was not responsible for the
onset.
AD animal models used to study retinal degeneration have
produced a variety of results. Each AD animal model is unique
depending on its mutation (Ex. Tg2576 single transgenic and
APP/PS1 double transgenic), resulting in slightly different
outcomes such as the detection of α- and β- secretase in
Tg2576 but not in the double transgenic model. However, all
the models produce similar results such as the measurements
of Aβ formation and increased microglia activity. These results
lead to the thought that vision impairment is partly due to the
interference effect leading to disrupted neuronal transmission
or neuronal cell loss. Current models contribute their own part
to AD pathology, but vary in many measures. A more complete
and comparable animal model design may connect the critical
but subtle differences between the models. This will lead to a
more comprehensive understanding of AD.
VI. IMPLICATIONS FOR FUTURE RESEARCH
AD animal models for AD in humans, differs substantially
due in part to unique evolutionary pressures. Being geneti-
cally, biochemically and biophysically different, means animal
models can only contribute in a limited capacity. Despite this,
animal models have contributed much to our understanding
of AD pathology. This may ultimately lead to the detection
and treatment of AD one day. Contradictory and different
findings in studies using mouse models may result from both
the identity and quantity of mutation genes that mimic the
pathology of AD in humans. Greater number of transgenes
incorporated, appears to increase the variety of abnormalities
seen. As most models used for studying AD and retinal
degeneration relationships differ in the results, researchers
should select the model that best suit their pathway of interest.
Increasing evidence links AD with retinal degeneration.
This represents significant progress in understanding AD and
serves as a possible early detection method of AD and
other neurodegenerative diseases. Recent studies looking at
retinal degeneration diseases such as glaucoma and AMD,
suggest neuronal losses are due to Aβ or Aβ like deposits
leading to neuronal loss in the retina. Despite anatomical
and physiological differences, animal models have contributed
and will continue to contribute to the key understanding of
neurodegenerative diseases.
Studying the relations of retinal degeneration and AD is an
easier task in animal models than in humans. The time and
cost is significantly reduced when compared to studying the
relation in humans. This will increase the output of research
correlating AD with vision loss and hence will increase the
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chance that a correct link will be established between retinal
degeneration and AD.
Determining the correct mechanism and link between the
two will introduce a whole new direction of research into
treatment, intervention and early detection of AD or retinal
degeneration. Vision loss is often one of the first symptoms
most apparent in AD and other neurodegenerative diseases.
Eyes are being viewed as a possible window into the brain and
a model to develop treatment for neurodegenerative diseases
such as AD. Although AD has been known for a century now,
early and accurate diagnosis of still remains a big challenge
[50].
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